Información del artículo
El Texto completo está disponible en PDF
References
[1.]
M. Lebwohl, E. Christophers, R. Langley, J.R. Orteno, J. Roberts, C.E. Griffiths.
An international, randomized, double blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Arch Dermatol, 139 (2003), pp. 719-727
[2.]
C.L. Leonardi.
Efalizumab: an overview.
J Am Acad Dermatol, 49 (2003), pp. 98-104
[3.]
A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, B.S. Goffe, et al.
A randomized trial of etanercept as monotherapy for psoriasis.
Arch Dermatol, 139 (2003), pp. 1627-1632
[4.]
S.R. Feldman, K.B. Gordon, M. Bala, R. Evans, S. Li, L.T. Dooley, et al.
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Br J Dermatol, 152 (2005), pp. 954-960
[5.]
C.J.M. Van der Vleuten, M.J.P. Gerritsen, P.M. Steijlen, E.M.G.J. de Jong, P.C.M. van der Kerkhof.
A therapeutic approach to erythrodermic psoriasis: report of a case and a discussion of therapeutic options.
Acta Derm Venereol (Stockh), 76 (1996), pp. 65-67
[6.]
F. Rongioletti, M. Borenstein, R. Kirsner, F. Kerdel.
Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
J Dermatol Treat, 14 (2003), pp. 222-225
[7.]
S. Lisby, R. Gniadeckl.
Infliximab (Remicade®) for acute, severe pustular and erythrodermic psoriasis.
Acta Derm Venereol, 84 (2004), pp. 247-248
[8.]
H. Heikkilä, A. Ranki, S. Cajanus, S.L. Karvonen.
Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Arch Dermatol, 141 (2005), pp. 1607-1610
[9.]
M. Esposito, A. Mazzotta, C. de Felice, M. Papoutsaki, S. Climenti.
Treatment of erythrodermic psoriasis with etanercept.
Br J Dermatol, 155 (2006), pp. 156-159
Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
